BiotechTube

AU-011

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-muscle-invasive Bladder Cancer

Conditions

Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder

Trial Timeline

Sep 26, 2022 → Mar 1, 2027

NCT ID
NCT05483868

About AU-011

AU-011 is a phase 1 stage product being developed by Aura Biosciences for Non-muscle-invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05483868. Target conditions include Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC.

What happened to similar drugs?

0 of 1 similar drugs in Non-muscle-invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (1)
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06643884Phase 2Recruiting
NCT05483868Phase 1Recruiting
NCT05266430Pre-clinicalTerminated
NCT04417530Phase 2Completed

Competing Products

2 competing products in Non-muscle-invasive Bladder Cancer

See all competitors
ProductCompanyStageHype Score
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39